uniQure N.V. (QURE) is a publicly traded Healthcare sector company. As of September 29, 2026, QURE trades at $22.19 with a market cap of $2.65B and a P/E ratio of -9.54. QURE moved -43.26% today. Year to date, QURE is +63.44%; over the trailing twelve months it is -27.99%. Its 52-week range spans $7.76 to $71.50. Analyst consensus is strong buy with an average price target of $66.88. Rallies surfaces QURE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
uniQure says AMT-130 data show 80% slowing on cUHDRS at 36 months in high-dose patients: uniQure said Phase I/II data showed 80% slowing on cUHDRS at 36 months in high-dose Huntington’s patients, with follow-up results extending through 48 months.
| Metric | Value |
|---|---|
| Price | $22.19 |
| Market Cap | $2.65B |
| P/E Ratio | -9.54 |
| EPS | $-4.03 |
| Dividend Yield | 0.00% |
| 52-Week High | $71.50 |
| 52-Week Low | $7.76 |
| Volume | 8.22M |
| Avg Volume | 0 |
| Revenue (TTM) | $18.67M |
| Net Income | $-252.21M |
| Gross Margin | 92.49% |
9 analysts cover QURE: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $66.88.